Serina Therapeutics, Inc.
No SEC Form 4 filings for $SER in the last 30 days.
See all $SER insider activity →Serina Therapeutics (SER) reported early positive results for SER-252 in advanced Parkinson's patients, showing sustained pharmacokinetics and clinical activity. The company is insider-backed and advancing toward key milestones, expanding its POZ platform pipeline.
Serina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 21, 2026, Serina Therapeutics, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each da
Serina Therapeutics (NYSE American: SER) said it completed enrollment and dosing of all eight patients in Cohort 1 of its Phase 1b registrational study for SER-252 in July 2026. Top-line data from the single-ascending-dose arm is targeted for 1H 2027. Q2 2026 operating expenses were $6.8M and net loss was $8.9M, with cash at $23.0M at June 30, 2026.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SER (Serina Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SER coverage spans corporate actions, technology and insider activity.
Positive early data may boost SER's valuation and attract partnership interest.
Potential dilution and up‑front cash could support R&D, but price impact depends on execution and market conditions.
Cohort 1 completion reduces near-term execution risk and sets up the next blinded safety review and subsequent dose-escalation decision.
Cohort 1 completion de-risks near-term execution and sets up the next safety review and dose-escalation decision, with top-line single-ascending-dose data targeted for 1H 2027.
The filing is a corporate governance and compensation update for the CEO, with limited direct implications for near-term fundamentals.
AlphAI scores every news story that mentions SER with an AI model for sentiment and relevance, and aggregates insider trades from Serina Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Serina Therapeutics (SER) reported early positive results for SER-252 in advanced Parkinson's patients, showing sustained pharmacokinetics and clinical activity. The company is insider-backed and advancing toward key milestones, expanding its POZ platform pipeline.
1 min readSerina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 21, 2026, Serina Therapeutics, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each da
1 min readSerina Therapeutics (NYSE American: SER) said it completed enrollment and dosing of all eight patients in Cohort 1 of its Phase 1b registrational study for SER-252 in July 2026. Top-line data from the single-ascending-dose arm is targeted for 1H 2027. Q2 2026 operating expenses were $6.8M and net loss was $8.9M, with cash at $23.0M at June 30, 2026.
6 min readSerina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates – Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 - – Top-line data from the single-ascending-dose arm targeted for the first half
4 min readSerina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 serina-aremploymentagreeme.htm EX-10.1 Document AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Steve Ledger) This Amended and Restated Employment Agreement (this “ Agreement ”) is made and entered into effective as of the 19th day of July, 2026 (the “ Restatement Date ”), b
3 min readSerina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 1 ser-20260723xappointmentof.htm 8-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 22, 2026
2 min readSerina Therapeutics (NYSE American: SER) said its independent Data Safety Monitoring Committee completed review of 72-hour sentinel dosing safety and tolerability in Cohort 1 of the Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease and recommended continued dosing. Additional Cohort 1 dosing is underway in the US and Australia, and the company now expects to finish enrollment and dosing ahead of end-Q3 2026.
4 min readBrannan Stephen K. purchased 1,000 shares of Serina Therapeutics, Inc. (SER) at $2.03 on 2026-07-07.
2 min readSerina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. ser-20260617 0001708599 12/31 false 0001708599 2026-06-17 2026-06-17 0001708599 2026-01-01 2026-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Rep
3 min readVenkatesan Jay purchased 589 shares of Serina Therapeutics, Inc. (SER) at $1.78 on 2026-05-22.
2 min read
